However, the relationship is not uniform: in a study of patients with metastatic BRAF V600E/K melanoma, Menzies et al. observed that while pyrexia was frequent and recurrent under dabrafenib + trametinib, it was not statistically associated with baseline characteristics or drug efficacy, cautioning against overinterpretation [40]. This evidence concerns the gene BRAF and melanoma.